Skip to main content
Log in

The long-term effect of cyproterone acetate on growth in girls with idiopathic precocious puberty

  • Endocrinology
  • Published:
European Journal of Pediatrics Aims and scope Submit manuscript

Abstract

To define the effect of cyproterone acetate (CPA) on statural growth, 25 girls with idiopathic precocious puberty who had been treated with CPA were studied retrospectively. The final height SDS was −1.12±1.16 (mean±SD). The daily CPA dose was negatively related to the final height SDS. We divided our subjects into two groups according to the daily CPA dose [low dose, 84.9±15.4 mg/m2 (n=19) vs high dose, 135.8±17.1 mg/m2 (n=6)]. In the low dose group, the difference of the final height SDS minus height SDS for bone age at the initiation of CPA treatment was 0.55±1.16 and final height SDS was −0.82±1.05. The final height was not significantly different from the target height in the low dose group subjects whose target heights were obtained. Since the increment of height age to the increment of bone age during the treatment was significantly less in the group needing and treated with high dose CPA, high doses of CPA may reduce growth velocity more than its suppressive effect on bone maturation. These results suggest that CPA has an effect on statural growth in girls whose clinical symptoms can be controlled with a low dose of CPA, although they have not been compared with final height in untreated Japanese girls.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

BA:

bone age

CA:

chronological age

CPA:

cyproterone acetate

HA:

height age

References

  1. Abe K, Matsuura N (1982) Impaired GH secretion due to prolonged treatment with cyproterone acetate. Endocrinol Jpn 29: 27–29

    Google Scholar 

  2. Comite F, Cutler GB Jr, Rivier J, Vale W, Loriaux DL, Crowley WF Jr (1981) Short-term treatment of idiopathic precocious puberty with a long acting analogue of luteinizing hormone releasing hormone. N Engl J Med 305: 1546–1550

    Google Scholar 

  3. Crowley WF Jr, Comite F, Vale W, Rivier J, Loriaux DL, Cutler GB Jr (1981) Therapeutic use of pituitary desensitization with long-acting LHRH agonist: a potential new treatment for idiopathic precocious puberty. J Clin Endocrinol Metab 52: 370–372

    Google Scholar 

  4. Fujimoto M, Yamori T, Oyama K, Nakagomi Y, Ota M, Nakano K, Kato K (1989) Urinary growth hormone and somatomedin-C during cyproterone acetate treatment in children with precocious puberty. Clin Endocrinol 37: 519–523 (in Japanese)

    Google Scholar 

  5. Girard J, Baumann JB, Bühler U, Zuppinger K, Haas HG, Staub JJ, Wyss HI (1978) Cyproterone acetate and ACTH adrenal function. J Clin Endocrinol Metab 47: 581–586

    Google Scholar 

  6. Greulich WW, Pyle SI (1959) Radiographic atlas of skeletal development of the hand and wrist, 2nd edn. Stanford, Stanford University Press

    Google Scholar 

  7. Heinze F, Teller WM, Fehm HL, Joos A (1978) The effect of cyproterone acetate on adrenal cortical function in children with precocious puberty Eur J Pediatr 128: 81–88

    Google Scholar 

  8. Kato K, Fujimoto M (1988) Luteinizing hormone releasing hormone agonist (buserelin) in the treatment of central precocious puberty. In: Imura H, et al (eds) Progress in endocrinology. Elsevier Science Publisher, Amsterdam pp 145–150

    Google Scholar 

  9. Kauli R, Laron Z (1980) Pubertal development in girls with sexual precocity after discontinuation of treatment with cyproterone acetate. Helv Paediatr Acta 35: 149–154

    Google Scholar 

  10. Kauli R, Pertzelan A, Prager-Lewin R, Grunebaum M, Laron Z (1976) Cyproterone acetate in treatment of precocious puberty. Arch Dis Child 51: 202–208

    Google Scholar 

  11. Koshimizu T, Kato K, Hibi I, Suwa S, Shimizu N (1981) A review of cases of precocious puberty treated with cyproterone acetate in Japan. Folia Endocrinol Jpn 57: 42–63 (in Japanese)

    Google Scholar 

  12. Kreiter M, Burstein S, Rosenfield RL, Moll GW Jr, Cara JF, Yousefzadeh DK, Cuttler L, Levitsky LLX (1990) Preserving adult height potential in girls with idiopathic true precocious puberty. J Pediatr 117: 364–370

    Google Scholar 

  13. Lee PA (1981) Medroxyprogesterone therapy for sexual precocity in girls. Am J Dis Child 135: 443–445

    Google Scholar 

  14. Ogata T, Matsuo N, Tamai S, Osano M (1990) Target height and target range for the Japanese. J Jpn Pediatr Soc 94: 1535–1540 (in Japanese)

    Google Scholar 

  15. Schoevaart CE, Drop SLS, Otten BJ, Slijper FME, Degenhart HJ (1990) Growth analysis up to final height and psychosocial adjustment of treated and untreated patients with precocious puberty. Horm Res 34: 197–203

    Google Scholar 

  16. Sorgo W, Kiraly E, Homoki J, Heinze E, Teller WM, Bierich JR, Moeller H, Ranke MB, Butenandt O, Knorr D (1987) The effects of cyproterone acetate on statural growth in children with precocious puberty. Acta Endocrinol 115: 44–56

    Google Scholar 

  17. Stanhope R, Huen K-F, Buzi F, Preece MA, Grant DB (1987) The effect of cyproterone acetate on the growth of children with central precocious puberty. Eur J Pediatr 146: 500–503

    Google Scholar 

  18. Stahnke N, Ilicki A, Willig RP (1979) Effect of cyproterone acetate (CA) on growth and endocrine function in precocious puberty. Acta Paediatr Scand [Suppl] 277: 32–40

    Google Scholar 

  19. Stivel MS, Kauli R, Kaufman H, Laron Z (1982) Adrenocortical function in children with precocious sexual development during treatment with cyproterone acetate. Clin Endocrinol 16: 163–169

    Google Scholar 

  20. Werder EA, Mürset G, Zachmann M, Brook CGD, Prader A (1974) Treatment of precocious puberty with cyproterone acetate. Pediatr Res 8: 248–256

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Consortia

Additional information

Androcur Study Group consists of the following personnel: K. Fujieda, Department of Paediatrics, Hokkaido University School of Medicine; A. Okuno, Department of Paediatrics, Asahikawa Medical College; K. Sanayama, Department of Paediatrics, Chiba University School of Medicine; K. Shimozawa, Department of Paediatrics, Tokyo Medical and Dental University School of Medicine; N. Matsuo, Department of Paediatrics, Keio Gijuku University School of Medicine; Y. Oyama, Department of Paediatrics, Kitasato University School of Medicine; Y. Igarashi, Department of Paediatrics, Hamamatsu Medical College; M. Ogawa, Department of Paediatrics, Nagoya University School of Medicine; S. Okada, Department of Paediatrics, Osaka University School of Medicine; T. Kondo, Third department of Internal Medicine, Osaka Children's Medical Centre; Y. Nishi, Department of Paediatrics, Hiroshima Red Cross Hospital

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kato, K., Fujimoto, M., Hibi, I. et al. The long-term effect of cyproterone acetate on growth in girls with idiopathic precocious puberty. Eur J Pediatr 152, 297–300 (1993). https://doi.org/10.1007/BF01956737

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01956737

Key words

Navigation